In summary, our study shows that patients with HER2-positive breast cancer, tumor grade 3, estrogen receptor negativity, progesterone negativity, strong HER2 positivity (score 3+), and the use of neoadjuvant trastuzumab have higher pathological complete response rates. Here, ERBB2 is linked to breast carcinoma.